FDA/Industry Workshop September 14-16, 2005 Critical Path Initiative: What it means for pharmaceutical industry statisticians Walter Offen, Lilly Brenda.
C URE T HE P ROCESS 2: Improving the Development Process for Rare Disease Treatments Emil D. Kakkis, M.D., Ph.D. President and Founder October 29, 2014.
